Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspectiveStephen Chaplin, Edward Li, Joris van Stiphout et al.|Journal of Managed Care & Specialty Pharmacy|2024Cited by 5
Budget Impact Analysis of Biosimilar Natalizumab in the USEdward Li, Daniel M. Hartung, Soni Gupta et al.|The American Journal of Managed Care|2024Cited by 4
CO91 Real-World Events Often Associated with Relapse (EOAR) Rates Among Patients with Multiple Sclerosis on Natalizumab Using Claims Data from the PearlDiver Mariner DatabaseAnna Chen, Edward Li, James Hunt et al.|Value in Health|2025Cited by 0